Sherer R, Adeyemi OM, Simeone E, Despotes J, Tschampa J; International Conference on AIDS (15th : 2004 : Bangkok, Thailand).
Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. B10238.
CORE Center, Cook County Hospital, Chicago, United States
Background: To describe the efficacy, durability and tolerability of Lopinavir/r (LPV/r) based HAART regimens in an urban clinic population. Methods: A retrospective-prospective observational study. Between Oct 2002 and Oct 2003, HIV+ patients currently receiving LPV/r were enrolled in this study. Baseline information collected included demographics, Hepatitis B/C sero-status, antiretroviral history, baseline and nadir CD4. At each study visit, data on LFTs, CD4, VL, lipids, ARV changes were collected, and waist/hip measurements were performed. Initial data on the first 12 weeks of study follow up are presented. Results: 120 HIV+ pts who had received LPV/r for a median duration of 6 months (0-41 months) were enrolled. The mean age was 44 years, 77% were male, 74% AA, 17% Caucasian and 8% Hispanic. At baseline (initiation of LPV/r) 18 pts (15%) were ARV naive, 66 pts (55%) had prior NNRTI experience; 79 pts (66%) had prior PI; 51pts (43%) had prior 3 class experience. In addition to LPV/r, 105 pts (91%) received NRTI's, 37pts (32%) NNRTI's and 15 (13%) a 2nd PI. At baseline the median CD4 and HIV RNA of the cohort were 177/mm[3] and 4.34 log10copies/ml. CD4 and HIV RNA changes shown in the table (all values median). Conclusions: In this diverse study population in a "real world" setting, there was a sustained immunologic and virologic response to LPV/r based regimens with the greatest benefits in treatment naive patients. [table: see text]
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antigens, CD4
- Antiretroviral Therapy, Highly Active
- HIV Infections
- HIV Seropositivity
- HIV-1
- Humans
- Longitudinal Studies
- Male
- Pyrimidinones
- Retroviridae
- Virion
- immunology
- lopinavir
- virology
Other ID:
UI: 102276411
From Meeting Abstracts